Envestnet Asset Management Inc. Sells 2,463 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Envestnet Asset Management Inc. lowered its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 7.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 32,203 shares of the company’s stock after selling 2,463 shares during the quarter. Envestnet Asset Management Inc. owned about 0.07% of Amphastar Pharmaceuticals worth $1,196,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Pacer Advisors Inc. raised its position in shares of Amphastar Pharmaceuticals by 51,977.4% in the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock worth $50,139,000 after purchasing an additional 1,347,775 shares during the last quarter. D.A. Davidson & CO. purchased a new position in shares of Amphastar Pharmaceuticals in the 4th quarter worth about $417,000. Barclays PLC raised its position in shares of Amphastar Pharmaceuticals by 53.3% in the 3rd quarter. Barclays PLC now owns 74,456 shares of the company’s stock worth $3,613,000 after purchasing an additional 25,878 shares during the last quarter. Polaris Capital Management LLC purchased a new position in shares of Amphastar Pharmaceuticals in the 4th quarter worth about $910,000. Finally, Dynamic Technology Lab Private Ltd raised its position in shares of Amphastar Pharmaceuticals by 309.0% in the 4th quarter. Dynamic Technology Lab Private Ltd now owns 19,150 shares of the company’s stock worth $711,000 after purchasing an additional 14,468 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Trading Down 0.4 %

Shares of NASDAQ:AMPH opened at $24.41 on Thursday. The stock has a 50 day moving average of $26.63 and a 200 day moving average of $36.11. The company has a market cap of $1.16 billion, a PE ratio of 8.14, a price-to-earnings-growth ratio of 2.19 and a beta of 0.79. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 12-month low of $22.64 and a 12-month high of $53.96.

Insider Activity at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the sale, the chief financial officer now owns 97,363 shares in the company, valued at $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 27.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Piper Sandler cut their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research note on Friday, March 21st.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.